Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 11

1675P - Impact of adjuvant hormonal therapy on sexual and global quality of life in young egyptian women with breast cancer

Date

14 Sep 2024

Session

Poster session 11

Topics

Cancer in Adolescents and Young Adults (AYA);  Psycho-Oncology;  Survivorship;  Cancer Research

Tumour Site

Breast Cancer

Presenters

Omnia Korani

Citation

Annals of Oncology (2024) 35 (suppl_2): S1004-S1011. 10.1016/annonc/annonc1608

Authors

O.M. Korani1, S.A. Samy1, R. Eid2, A.M. Helal3, E. Shash1

Author affiliations

  • 1 Medical Oncology Department, National Cancer Institute - Cairo University, 11796 - Cairo/EG
  • 2 Biostatistics And Cancer Epidemiology, National Cancer Institute - Cairo University, 11796 - Cairo/EG
  • 3 Medical Oncology Department, Baheya Foundation for Early Detection & Treatment of Breast Cancer, 11796 - Cairo/EG

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1675P

Background

Adjuvant hormonal therapy (AHT) is integral to breast cancer management but often severely impacts the quality of life (QoL), especially concerning sexual functioning and psychological well-being. This study evaluates the effects of AHT on the sexual and global QoL of young breast cancer survivors.

Methods

This cross-sectional study was conducted at two cancer centers within Cairo, Egypt, involving 644 young breast cancer patients. The European Organization for Research and Treatment of Cancer EORTC QLQ - BR45 questionnaire was employed to assess the impact of AHT on sexual and global QoL. Data analysis encompassed demographic factors, treatment regimens, duration of therapy, functional and symptomatic scales of the questionnaire.

Results

The participants' median age was 41 years (range: 25-45), the primary AHT consisted of Tamoxifen + LHRH analogues (55.4%). there was a notable decrease in sexual enjoyment, with 50.7% of participants reporting no sexual activity in the past month. Among those who were sexually active, only 7.1% reported high enjoyment post-treatment compared to 31.5% pre-treatment. Additionally, 48.1% of patients experienced a complete lack of sexual desire post-treatment, while 38% expressed a significant need for psychological support. Analysis of the EORTC QLQ - BR45 questionnaire revealed Sexual Enjoyment Score: 52.9, Body image score 59.3, and Endocrine side effect score 49.4.

Conclusions

The findings reveal a profound impact of AHT on both the sexual and overall QoL among young breast cancer patients. The significant decline in sexual enjoyment and desire, coupled with a substantial need for psychological support, underscores the necessity for integrated care strategies that address the comprehensive health challenges faced by young breast cancer survivors.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

The authors.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.